Kevin Deane
Concepts (403)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arthritis, Rheumatoid | 109 | 2024 | 1004 | 17.930 |
Why?
| Autoantibodies | 62 | 2024 | 1362 | 7.310 |
Why?
| Rheumatoid Factor | 36 | 2023 | 157 | 5.650 |
Why?
| Anti-Citrullinated Protein Antibodies | 22 | 2023 | 90 | 4.520 |
Why?
| Autoimmunity | 22 | 2023 | 823 | 3.500 |
Why?
| Peptides, Cyclic | 29 | 2023 | 262 | 3.470 |
Why?
| Antirheumatic Agents | 11 | 2021 | 255 | 2.010 |
Why?
| Rheumatic Diseases | 4 | 2022 | 49 | 1.910 |
Why?
| Sputum | 4 | 2021 | 291 | 1.600 |
Why?
| Immunoglobulin A | 11 | 2023 | 173 | 1.270 |
Why?
| Lung Diseases, Interstitial | 8 | 2024 | 520 | 1.230 |
Why?
| Biomarkers | 27 | 2024 | 3474 | 1.110 |
Why?
| Humans | 132 | 2024 | 115907 | 1.080 |
Why?
| Autoantigens | 8 | 2023 | 399 | 1.080 |
Why?
| Disease Progression | 16 | 2021 | 2424 | 0.940 |
Why?
| Bronchial Diseases | 3 | 2013 | 38 | 0.940 |
Why?
| Early Medical Intervention | 2 | 2014 | 51 | 0.930 |
Why?
| Extracellular Traps | 3 | 2021 | 40 | 0.910 |
Why?
| Genetic Predisposition to Disease | 16 | 2023 | 2209 | 0.900 |
Why?
| Lung Diseases | 4 | 2022 | 710 | 0.830 |
Why?
| Rheumatology | 6 | 2021 | 89 | 0.820 |
Why?
| Early Diagnosis | 8 | 2022 | 221 | 0.810 |
Why?
| Mosquito Vectors | 1 | 2022 | 21 | 0.810 |
Why?
| Inflammation | 9 | 2023 | 2503 | 0.800 |
Why?
| Insecticides | 1 | 2022 | 31 | 0.800 |
Why?
| Lupus Erythematosus, Systemic | 4 | 2022 | 222 | 0.790 |
Why?
| Joints | 4 | 2015 | 84 | 0.780 |
Why?
| Precision Medicine | 3 | 2020 | 356 | 0.780 |
Why?
| Malaria | 1 | 2022 | 48 | 0.780 |
Why?
| Arthralgia | 2 | 2021 | 50 | 0.760 |
Why?
| Prodromal Symptoms | 1 | 2020 | 12 | 0.750 |
Why?
| Risk Factors | 29 | 2022 | 8714 | 0.750 |
Why?
| Middle Aged | 62 | 2022 | 27084 | 0.750 |
Why?
| Epitopes | 8 | 2023 | 438 | 0.730 |
Why?
| Histones | 4 | 2023 | 539 | 0.680 |
Why?
| Female | 78 | 2023 | 60086 | 0.680 |
Why?
| Lung | 7 | 2020 | 3685 | 0.670 |
Why?
| Citrullination | 2 | 2020 | 12 | 0.670 |
Why?
| Male | 67 | 2022 | 56128 | 0.660 |
Why?
| Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 794 | 0.660 |
Why?
| HIV Infections | 3 | 2021 | 2469 | 0.620 |
Why?
| Methotrexate | 3 | 2021 | 228 | 0.610 |
Why?
| Mucous Membrane | 1 | 2018 | 108 | 0.600 |
Why?
| Immunoglobulin G | 11 | 2023 | 782 | 0.600 |
Why?
| Asymptomatic Diseases | 2 | 2021 | 77 | 0.590 |
Why?
| Adult | 48 | 2022 | 30820 | 0.580 |
Why?
| Pedigree | 2 | 2020 | 474 | 0.570 |
Why?
| Citrulline | 2 | 2016 | 39 | 0.560 |
Why?
| Synovitis | 2 | 2023 | 24 | 0.560 |
Why?
| Case-Control Studies | 15 | 2023 | 3054 | 0.540 |
Why?
| Antibodies, Anti-Idiotypic | 2 | 2015 | 54 | 0.540 |
Why?
| Transients and Migrants | 1 | 2016 | 22 | 0.540 |
Why?
| Human Migration | 1 | 2016 | 21 | 0.540 |
Why?
| Autoimmune Diseases | 4 | 2023 | 396 | 0.530 |
Why?
| Arthritis | 2 | 2016 | 110 | 0.520 |
Why?
| Aged | 34 | 2022 | 19299 | 0.510 |
Why?
| Immunoglobulin M | 7 | 2023 | 251 | 0.510 |
Why?
| Family | 7 | 2021 | 591 | 0.480 |
Why?
| Cytokines | 10 | 2023 | 1857 | 0.480 |
Why?
| Pneumonia | 1 | 2020 | 576 | 0.480 |
Why?
| Sexual Behavior | 2 | 2016 | 442 | 0.470 |
Why?
| Prospective Studies | 19 | 2022 | 6267 | 0.470 |
Why?
| Endothelium, Vascular | 4 | 2013 | 845 | 0.440 |
Why?
| Risk-Taking | 1 | 2016 | 333 | 0.440 |
Why?
| Chemokines | 2 | 2012 | 214 | 0.430 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2013 | 43 | 0.430 |
Why?
| Risk Reduction Behavior | 1 | 2014 | 196 | 0.430 |
Why?
| Tanzania | 3 | 2021 | 44 | 0.420 |
Why?
| Hazardous Substances | 1 | 2012 | 11 | 0.420 |
Why?
| Observational Studies as Topic | 2 | 2024 | 89 | 0.410 |
Why?
| Mass Screening | 3 | 2020 | 1023 | 0.400 |
Why?
| Susac Syndrome | 1 | 2011 | 3 | 0.380 |
Why?
| Fatty Acids, Omega-3 | 3 | 2017 | 125 | 0.380 |
Why?
| Smoking | 9 | 2024 | 1468 | 0.370 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.370 |
Why?
| Protein Processing, Post-Translational | 1 | 2013 | 400 | 0.370 |
Why?
| Gene-Environment Interaction | 1 | 2012 | 194 | 0.370 |
Why?
| Emigration and Immigration | 1 | 2010 | 45 | 0.360 |
Why?
| Research Design | 3 | 2024 | 947 | 0.360 |
Why?
| Malondialdehyde | 2 | 2020 | 26 | 0.360 |
Why?
| Acetaldehyde | 2 | 2020 | 20 | 0.360 |
Why?
| Postmenopause | 7 | 2023 | 301 | 0.350 |
Why?
| Health Fairs | 1 | 2009 | 9 | 0.350 |
Why?
| Antibodies, Antinuclear | 5 | 2023 | 60 | 0.350 |
Why?
| Glucocorticoids | 3 | 2021 | 551 | 0.320 |
Why?
| Antibodies, Bacterial | 3 | 2023 | 119 | 0.320 |
Why?
| Incidence | 9 | 2021 | 2333 | 0.320 |
Why?
| Mucin-5B | 2 | 2022 | 185 | 0.310 |
Why?
| Synovial Membrane | 3 | 2023 | 74 | 0.310 |
Why?
| Health Behavior | 3 | 2018 | 707 | 0.290 |
Why?
| Cross-Sectional Studies | 9 | 2023 | 4449 | 0.290 |
Why?
| Antibody Formation | 4 | 2023 | 273 | 0.270 |
Why?
| Antibodies, Antiphospholipid | 1 | 2005 | 21 | 0.260 |
Why?
| Vasculitis | 1 | 2005 | 71 | 0.250 |
Why?
| Risk Assessment | 6 | 2020 | 3004 | 0.240 |
Why?
| Qualitative Research | 2 | 2021 | 964 | 0.230 |
Why?
| Polysaccharides | 2 | 2017 | 79 | 0.230 |
Why?
| Risk | 3 | 2016 | 830 | 0.220 |
Why?
| Estrogens | 3 | 2017 | 316 | 0.220 |
Why?
| Time Factors | 6 | 2019 | 6186 | 0.220 |
Why?
| Protein-Arginine Deiminases | 3 | 2021 | 17 | 0.210 |
Why?
| Mouth Mucosa | 3 | 2023 | 80 | 0.210 |
Why?
| Periodontal Diseases | 1 | 2023 | 58 | 0.210 |
Why?
| Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.210 |
Why?
| Trichloroethylene | 1 | 2022 | 7 | 0.210 |
Why?
| Biological Products | 2 | 2022 | 172 | 0.210 |
Why?
| Insecticide-Treated Bednets | 1 | 2022 | 3 | 0.210 |
Why?
| Prevalence | 4 | 2022 | 2270 | 0.200 |
Why?
| Patient Education as Topic | 2 | 2018 | 686 | 0.200 |
Why?
| Women's Health | 5 | 2017 | 271 | 0.200 |
Why?
| Sex Factors | 5 | 2020 | 1741 | 0.200 |
Why?
| Hemorrhage | 1 | 2005 | 616 | 0.190 |
Why?
| Organ Specificity | 2 | 2019 | 274 | 0.190 |
Why?
| Epstein-Barr Virus Infections | 1 | 2022 | 71 | 0.190 |
Why?
| Housing | 1 | 2022 | 115 | 0.190 |
Why?
| Retrospective Studies | 5 | 2024 | 12616 | 0.190 |
Why?
| Sarcoidosis | 1 | 2022 | 133 | 0.190 |
Why?
| Fatty Acids, Unsaturated | 1 | 2021 | 86 | 0.180 |
Why?
| Neutrophil Activation | 1 | 2021 | 93 | 0.180 |
Why?
| Hydroxychloroquine | 1 | 2020 | 55 | 0.180 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.180 |
Why?
| Chemokine CXCL16 | 1 | 2020 | 4 | 0.180 |
Why?
| Severity of Illness Index | 8 | 2022 | 2598 | 0.180 |
Why?
| Social Stigma | 1 | 2021 | 90 | 0.180 |
Why?
| Complement System Proteins | 2 | 2022 | 288 | 0.180 |
Why?
| Museums | 1 | 2000 | 7 | 0.180 |
Why?
| Intestines | 2 | 2021 | 325 | 0.170 |
Why?
| Animals | 8 | 2022 | 32123 | 0.170 |
Why?
| Sjogren's Syndrome | 1 | 2020 | 42 | 0.170 |
Why?
| Bacteriophages | 1 | 2021 | 76 | 0.170 |
Why?
| Toll-Like Receptors | 1 | 2020 | 166 | 0.170 |
Why?
| Art Therapy | 1 | 2000 | 14 | 0.170 |
Why?
| Muramidase | 1 | 2020 | 73 | 0.170 |
Why?
| Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.170 |
Why?
| Cytomegalovirus Infections | 1 | 2022 | 181 | 0.170 |
Why?
| Lipopolysaccharide Receptors | 1 | 2020 | 85 | 0.170 |
Why?
| Age Factors | 7 | 2020 | 2912 | 0.170 |
Why?
| Attitude | 1 | 2021 | 231 | 0.170 |
Why?
| Occupational Exposure | 1 | 2022 | 262 | 0.170 |
Why?
| Young Adult | 8 | 2021 | 10518 | 0.170 |
Why?
| Nuclear Family | 1 | 2019 | 53 | 0.170 |
Why?
| Inflammation Mediators | 2 | 2020 | 481 | 0.160 |
Why?
| Gain of Function Mutation | 1 | 2018 | 30 | 0.160 |
Why?
| Dexamethasone | 1 | 2020 | 315 | 0.160 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 46 | 0.160 |
Why?
| Gene Expression | 2 | 2022 | 1442 | 0.160 |
Why?
| Arthritis, Experimental | 1 | 2020 | 133 | 0.160 |
Why?
| Cohort Studies | 10 | 2022 | 4960 | 0.160 |
Why?
| Cellular Senescence | 1 | 2019 | 153 | 0.150 |
Why?
| Monocytes | 1 | 2020 | 504 | 0.150 |
Why?
| Vascular Stiffness | 2 | 2013 | 411 | 0.150 |
Why?
| Global Health | 1 | 2020 | 292 | 0.150 |
Why?
| HLA-DR4 Antigen | 3 | 2007 | 76 | 0.150 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 503 | 0.150 |
Why?
| Metabolome | 1 | 2020 | 286 | 0.150 |
Why?
| Remission Induction | 2 | 2021 | 240 | 0.150 |
Why?
| United States | 8 | 2022 | 12338 | 0.150 |
Why?
| Galactose | 1 | 2017 | 20 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2021 | 1138 | 0.140 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 945 | 0.140 |
Why?
| Military Personnel | 2 | 2021 | 526 | 0.140 |
Why?
| Glycosylation | 1 | 2017 | 133 | 0.140 |
Why?
| Adiponectin | 1 | 2018 | 213 | 0.140 |
Why?
| Coronary Disease | 2 | 2017 | 349 | 0.140 |
Why?
| Seroepidemiologic Studies | 3 | 2014 | 141 | 0.140 |
Why?
| Estradiol | 3 | 2017 | 453 | 0.140 |
Why?
| Idiopathic Pulmonary Fibrosis | 2 | 2019 | 511 | 0.140 |
Why?
| Plasma Cells | 1 | 2016 | 57 | 0.140 |
Why?
| Sex Work | 1 | 2016 | 18 | 0.140 |
Why?
| Hydrolases | 2 | 2021 | 52 | 0.140 |
Why?
| Sensitivity and Specificity | 3 | 2018 | 1728 | 0.130 |
Why?
| HLA Antigens | 1 | 2017 | 224 | 0.130 |
Why?
| Diet | 2 | 2020 | 1075 | 0.130 |
Why?
| Diagnosis, Differential | 3 | 2013 | 1359 | 0.130 |
Why?
| Peptides | 1 | 2021 | 862 | 0.130 |
Why?
| Cardiovascular Diseases | 3 | 2017 | 1724 | 0.130 |
Why?
| Mitochondria | 1 | 2021 | 753 | 0.130 |
Why?
| Neutrophils | 1 | 2021 | 1170 | 0.130 |
Why?
| Adaptation, Psychological | 1 | 2000 | 551 | 0.130 |
Why?
| Vasodilation | 3 | 2013 | 413 | 0.120 |
Why?
| Neoplasms | 2 | 2017 | 2112 | 0.120 |
Why?
| Alcohol Drinking | 1 | 2020 | 654 | 0.120 |
Why?
| Tertiary Prevention | 1 | 2014 | 3 | 0.120 |
Why?
| Focus Groups | 1 | 2016 | 386 | 0.120 |
Why?
| C-Reactive Protein | 5 | 2018 | 364 | 0.120 |
Why?
| Drug Therapy, Combination | 2 | 2021 | 961 | 0.120 |
Why?
| Blood Pressure | 2 | 2017 | 1536 | 0.110 |
Why?
| Respiratory Mucosa | 1 | 2016 | 261 | 0.110 |
Why?
| Secondary Prevention | 1 | 2014 | 223 | 0.110 |
Why?
| Bacteroidaceae Infections | 1 | 2012 | 4 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2020 | 847 | 0.110 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 140 | 0.110 |
Why?
| Porphyromonas gingivalis | 1 | 2012 | 17 | 0.110 |
Why?
| Primary Prevention | 1 | 2014 | 171 | 0.110 |
Why?
| Vitamin D | 2 | 2022 | 341 | 0.110 |
Why?
| Family Health | 2 | 2013 | 199 | 0.110 |
Why?
| Immune Tolerance | 1 | 2014 | 331 | 0.110 |
Why?
| Stress, Psychological | 1 | 2020 | 975 | 0.110 |
Why?
| Population Surveillance | 1 | 2015 | 396 | 0.100 |
Why?
| Periodontitis | 1 | 2012 | 42 | 0.100 |
Why?
| Health | 1 | 2012 | 74 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2023 | 1870 | 0.100 |
Why?
| Arthrography | 1 | 2011 | 22 | 0.100 |
Why?
| Telomere Shortening | 2 | 2024 | 18 | 0.100 |
Why?
| Predictive Value of Tests | 3 | 2013 | 1817 | 0.100 |
Why?
| Delayed Diagnosis | 1 | 2012 | 72 | 0.100 |
Why?
| Pneumonia, Bacterial | 1 | 2013 | 108 | 0.100 |
Why?
| Proportional Hazards Models | 3 | 2021 | 1088 | 0.100 |
Why?
| Follow-Up Studies | 4 | 2019 | 4446 | 0.100 |
Why?
| Disease Susceptibility | 3 | 2021 | 321 | 0.100 |
Why?
| Time-to-Treatment | 1 | 2012 | 147 | 0.100 |
Why?
| Phenotype | 4 | 2023 | 2861 | 0.100 |
Why?
| Reproducibility of Results | 3 | 2020 | 2814 | 0.090 |
Why?
| Longitudinal Studies | 4 | 2020 | 2437 | 0.090 |
Why?
| Logistic Models | 5 | 2020 | 1865 | 0.090 |
Why?
| Labor, Induced | 1 | 2011 | 32 | 0.090 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 80 | 0.090 |
Why?
| Air Pollution | 1 | 2013 | 183 | 0.090 |
Why?
| Cyclophosphamide | 1 | 2011 | 218 | 0.090 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1193 | 0.090 |
Why?
| Rituximab | 1 | 2011 | 149 | 0.090 |
Why?
| Immunoglobulins, Intravenous | 1 | 2011 | 123 | 0.090 |
Why?
| Vasodilator Agents | 1 | 2012 | 308 | 0.090 |
Why?
| Colorado | 3 | 2020 | 4122 | 0.090 |
Why?
| Statistics, Nonparametric | 1 | 2010 | 390 | 0.090 |
Why?
| Treatment Outcome | 3 | 2021 | 9166 | 0.090 |
Why?
| Menopause | 1 | 2012 | 262 | 0.090 |
Why?
| Aging | 1 | 2019 | 1640 | 0.080 |
Why?
| Community-Institutional Relations | 1 | 2009 | 89 | 0.080 |
Why?
| Respiratory Insufficiency | 1 | 2013 | 292 | 0.080 |
Why?
| Interleukin-6 | 3 | 2021 | 679 | 0.080 |
Why?
| Aspirin | 1 | 2011 | 326 | 0.080 |
Why?
| Obesity | 1 | 2020 | 2530 | 0.080 |
Why?
| Odds Ratio | 3 | 2018 | 969 | 0.080 |
Why?
| Alleles | 3 | 2019 | 818 | 0.080 |
Why?
| Disease Outbreaks | 1 | 2010 | 309 | 0.080 |
Why?
| Societies, Medical | 2 | 2021 | 690 | 0.070 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 510 | 0.070 |
Why?
| Brachial Artery | 3 | 2013 | 174 | 0.070 |
Why?
| Stroke | 1 | 2015 | 1014 | 0.070 |
Why?
| Contraceptives, Oral, Hormonal | 1 | 2006 | 23 | 0.070 |
Why?
| Capillaries | 1 | 2005 | 93 | 0.060 |
Why?
| Environment | 2 | 2019 | 339 | 0.060 |
Why?
| Premenopause | 2 | 2017 | 104 | 0.060 |
Why?
| Radiography, Thoracic | 1 | 2005 | 165 | 0.060 |
Why?
| Arthritis, Juvenile | 1 | 2005 | 42 | 0.060 |
Why?
| Healthy Volunteers | 2 | 2017 | 191 | 0.060 |
Why?
| Bronchoscopy | 1 | 2005 | 245 | 0.060 |
Why?
| Immunity, Mucosal | 2 | 2014 | 85 | 0.060 |
Why?
| Interleukin-2 | 2 | 2016 | 414 | 0.060 |
Why?
| Phosphopyruvate Hydratase | 1 | 2023 | 30 | 0.050 |
Why?
| Pulmonary Alveoli | 1 | 2005 | 376 | 0.050 |
Why?
| Vimentin | 1 | 2023 | 58 | 0.050 |
Why?
| Antibodies | 1 | 2005 | 374 | 0.050 |
Why?
| Body Mass Index | 2 | 2020 | 1982 | 0.050 |
Why?
| Surveys and Questionnaires | 2 | 2014 | 4670 | 0.050 |
Why?
| Biopsy | 1 | 2005 | 1056 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2021 | 1444 | 0.050 |
Why?
| Immunoglobulins | 2 | 2015 | 148 | 0.050 |
Why?
| Telomere | 1 | 2024 | 205 | 0.050 |
Why?
| Immunosuppressive Agents | 1 | 2005 | 666 | 0.050 |
Why?
| Janus Kinase Inhibitors | 1 | 2021 | 10 | 0.050 |
Why?
| Tissue Distribution | 1 | 2022 | 324 | 0.050 |
Why?
| Herpesvirus 4, Human | 1 | 2022 | 123 | 0.050 |
Why?
| Carotid Arteries | 2 | 2013 | 183 | 0.050 |
Why?
| Hydroxyeicosatetraenoic Acids | 1 | 2021 | 40 | 0.050 |
Why?
| Mice | 3 | 2022 | 15075 | 0.050 |
Why?
| Xenobiotics | 1 | 2021 | 24 | 0.050 |
Why?
| Putrescine | 1 | 2020 | 2 | 0.050 |
Why?
| Vitamins | 1 | 2022 | 151 | 0.050 |
Why?
| Butyric Acid | 1 | 2020 | 5 | 0.050 |
Why?
| Microbiota | 2 | 2021 | 651 | 0.050 |
Why?
| Genetic Markers | 1 | 2022 | 337 | 0.050 |
Why?
| Docosahexaenoic Acids | 1 | 2021 | 69 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2012 | 2409 | 0.050 |
Why?
| Spermidine | 1 | 2020 | 18 | 0.050 |
Why?
| Caprylates | 1 | 2020 | 22 | 0.050 |
Why?
| Europe | 1 | 2021 | 352 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2010 | 3582 | 0.050 |
Why?
| Phosphatidylethanolamines | 1 | 2020 | 66 | 0.050 |
Why?
| Carnitine | 1 | 2020 | 61 | 0.050 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.050 |
Why?
| Chemokine CXCL13 | 1 | 2020 | 7 | 0.050 |
Why?
| B-Cell Activating Factor | 1 | 2020 | 18 | 0.050 |
Why?
| Survival Analysis | 2 | 2017 | 1221 | 0.040 |
Why?
| Synovial Fluid | 1 | 2020 | 57 | 0.040 |
Why?
| Chemokine CXCL9 | 1 | 2020 | 22 | 0.040 |
Why?
| Interleukin-8 | 1 | 2021 | 243 | 0.040 |
Why?
| Acute-Phase Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| Methionine | 1 | 2020 | 145 | 0.040 |
Why?
| Chemokine CXCL10 | 1 | 2020 | 36 | 0.040 |
Why?
| Immunophenotyping | 1 | 2020 | 273 | 0.040 |
Why?
| Fluorescent Antibody Technique | 1 | 2020 | 399 | 0.040 |
Why?
| Interleukin-1alpha | 1 | 2020 | 55 | 0.040 |
Why?
| Antibody Specificity | 1 | 2020 | 180 | 0.040 |
Why?
| Ontario | 1 | 2000 | 108 | 0.040 |
Why?
| Interinstitutional Relations | 1 | 2000 | 55 | 0.040 |
Why?
| Tryptophan | 1 | 2020 | 136 | 0.040 |
Why?
| Baltimore | 1 | 2019 | 43 | 0.040 |
Why?
| Prognosis | 2 | 2021 | 3342 | 0.040 |
Why?
| International Cooperation | 1 | 2020 | 175 | 0.040 |
Why?
| Pregnancy | 1 | 2011 | 5556 | 0.040 |
Why?
| Interferons | 1 | 2020 | 152 | 0.040 |
Why?
| Endotoxins | 1 | 2020 | 208 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 631 | 0.040 |
Why?
| Consensus | 1 | 2021 | 533 | 0.040 |
Why?
| Interleukin-1beta | 1 | 2021 | 370 | 0.040 |
Why?
| Clinical Decision-Making | 1 | 2021 | 275 | 0.040 |
Why?
| Genotype | 2 | 2018 | 1842 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2023 | 771 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2022 | 520 | 0.040 |
Why?
| Epitopes, B-Lymphocyte | 1 | 2018 | 15 | 0.040 |
Why?
| Dysbiosis | 1 | 2020 | 145 | 0.040 |
Why?
| Nurses | 1 | 2020 | 150 | 0.040 |
Why?
| Reactive Oxygen Species | 1 | 2021 | 552 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 233 | 0.040 |
Why?
| Forecasting | 1 | 2020 | 332 | 0.040 |
Why?
| Interleukins | 1 | 2020 | 237 | 0.040 |
Why?
| Genetic Testing | 1 | 2020 | 385 | 0.040 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2023 | 686 | 0.040 |
Why?
| Membrane Glycoproteins | 1 | 2020 | 429 | 0.040 |
Why?
| Gene Frequency | 1 | 2019 | 507 | 0.040 |
Why?
| Decision Support Techniques | 1 | 2021 | 352 | 0.040 |
Why?
| Phylogeny | 1 | 2021 | 802 | 0.040 |
Why?
| Amino Acids | 1 | 2021 | 455 | 0.040 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2019 | 2020 | 0.040 |
Why?
| Goserelin | 1 | 2017 | 8 | 0.040 |
Why?
| Raloxifene Hydrochloride | 1 | 2017 | 13 | 0.040 |
Why?
| Fertility Agents, Female | 1 | 2017 | 19 | 0.040 |
Why?
| Selective Estrogen Receptor Modulators | 1 | 2017 | 26 | 0.040 |
Why?
| Leuprolide | 1 | 2017 | 20 | 0.040 |
Why?
| Estrogens, Conjugated (USP) | 1 | 2017 | 34 | 0.040 |
Why?
| Genes, Immunoglobulin Light Chain | 1 | 2016 | 6 | 0.040 |
Why?
| Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.040 |
Why?
| Aromatase Inhibitors | 1 | 2017 | 49 | 0.040 |
Why?
| Phosphofructokinase-2 | 1 | 2016 | 14 | 0.040 |
Why?
| Bacteria | 1 | 2023 | 731 | 0.030 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 63 | 0.030 |
Why?
| Complement Activation | 1 | 2019 | 343 | 0.030 |
Why?
| Th17 Cells | 1 | 2016 | 58 | 0.030 |
Why?
| Adolescent | 4 | 2021 | 17955 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.030 |
Why?
| Models, Statistical | 1 | 2020 | 616 | 0.030 |
Why?
| Protective Factors | 1 | 2016 | 87 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2023 | 1758 | 0.030 |
Why?
| Carrier Proteins | 1 | 2020 | 703 | 0.030 |
Why?
| Patient Satisfaction | 1 | 2000 | 585 | 0.030 |
Why?
| Health Education | 1 | 2018 | 317 | 0.030 |
Why?
| Transcriptome | 1 | 2021 | 742 | 0.030 |
Why?
| Androgens | 1 | 2017 | 165 | 0.030 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2017 | 192 | 0.030 |
Why?
| Symptom Assessment | 1 | 2016 | 121 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2019 | 6438 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 295 | 0.030 |
Why?
| Hypercholesterolemia | 1 | 2015 | 91 | 0.030 |
Why?
| RNA, Messenger | 1 | 2022 | 2581 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2018 | 1129 | 0.030 |
Why?
| Motivation | 1 | 2018 | 496 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 336 | 0.030 |
Why?
| HLA-DRB1 Chains | 1 | 2014 | 99 | 0.030 |
Why?
| Etanercept | 1 | 2013 | 51 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 733 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 446 | 0.030 |
Why?
| Pneumocystis carinii | 1 | 2013 | 7 | 0.030 |
Why?
| Communication | 1 | 2018 | 749 | 0.030 |
Why?
| Geographic Information Systems | 1 | 2013 | 37 | 0.030 |
Why?
| Interleukin-9 | 1 | 2012 | 10 | 0.030 |
Why?
| Comorbidity | 1 | 2017 | 1476 | 0.030 |
Why?
| Cell Membrane | 1 | 2016 | 682 | 0.030 |
Why?
| Oral Health | 1 | 2014 | 145 | 0.030 |
Why?
| Dietary Supplements | 1 | 2016 | 460 | 0.030 |
Why?
| Life Style | 1 | 2014 | 428 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 286 | 0.030 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 139 | 0.030 |
Why?
| Immunologic Factors | 1 | 2014 | 219 | 0.020 |
Why?
| Connective Tissue Diseases | 1 | 2012 | 71 | 0.020 |
Why?
| Mutation | 1 | 2022 | 3370 | 0.020 |
Why?
| Exercise | 1 | 2021 | 1611 | 0.020 |
Why?
| Erythrocytes | 1 | 2016 | 590 | 0.020 |
Why?
| Particulate Matter | 1 | 2013 | 217 | 0.020 |
Why?
| Environmental Monitoring | 1 | 2013 | 281 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 1001 | 0.020 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 301 | 0.020 |
Why?
| Overweight | 1 | 2014 | 468 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2014 | 1090 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2012 | 541 | 0.020 |
Why?
| Internet | 1 | 2014 | 596 | 0.020 |
Why?
| Body Composition | 1 | 2013 | 581 | 0.020 |
Why?
| Self Report | 1 | 2013 | 701 | 0.020 |
Why?
| Interferon-gamma | 1 | 2012 | 731 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 671 | 0.020 |
Why?
| Diabetes Mellitus | 1 | 2015 | 906 | 0.020 |
Why?
| Hypertension | 1 | 2015 | 1063 | 0.020 |
Why?
| Algorithms | 1 | 2014 | 1494 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2016 | 2362 | 0.020 |
Why?
| Veterans | 1 | 2018 | 1232 | 0.020 |
Why?
| Bottle Feeding | 1 | 2007 | 20 | 0.020 |
Why?
| Histocompatibility Testing | 1 | 2007 | 116 | 0.020 |
Why?
| Tobacco Smoke Pollution | 1 | 2007 | 221 | 0.010 |
Why?
| Siblings | 1 | 2005 | 229 | 0.010 |
Why?
| Child | 2 | 2007 | 18555 | 0.010 |
Why?
| Child, Preschool | 1 | 2007 | 9175 | 0.010 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2006 | 3258 | 0.010 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|